Here’s what you should know.
1. Researchers are hoping the approach will reduce cancer tumors by approximately 40 percent.
2. The trial centers on patients with inoperable tumors, with researchers expecting the trials to take two years.
3. Specifically, the trial will be the first to combine Nivolumab and Yittrium-90 SIR-Spheres microspheres radioembolization.
Y90 radioembolization treats patients with inoperable cancer, while Nivolumab enhances the body’s immune response to cancer cells. The NCC believes the drug has shown “very promising results for advanced liver cancer patients in ongoing studies.
4. The NCC is conducting the trial with three other Singapore-based medical institutions.
More articles on gastroenterology/endoscopy:
Aetna may completely withdraw from exchanges due to ACA uncertainty: 5 things to know
Payers increasing scrutiny of coding compliance
Medicaid spending totals $575.9B in 2016 — 9 key points
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
